15-Apr-2026 6:05 AM CST - Business Wire Ionis to hold first quarter 2026 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invente
25-Feb-2026 6:00 AM CST - Business Wire Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026, said Brett P. Monia, Ph.D., chief executive officer of Ionis. This year,
19-Feb-2026 6:05 AM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Virtual Conference on Thursday, February 26, 2026 TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 Leerink Global Healthcare Conference on Monday, March 9, 2026 Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 Stifel
17-Feb-2026 1:58 PM CST - Business Wire Ionis updates time for fourth quarter and full year 2025 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live webcast, previously scheduled for 11:30 a.m. Eastern Time, will now be held at 8:30 a.m. Eastern Time on Wednesday, February 25. The date of the call remains unchanged. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limi
11-Feb-2026 6:05 AM CST - Business Wire Ionis to hold fourth quarter and full year 2025 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades
6-Jan-2026 6:05 AM CST - Business Wire Ionis to present at 44th Annual J.P. Morgan Healthcare Conference Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference at 8:15 a.m. PT on Tuesday, January 13, 2026. A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events. A replay will be available on the Ionis website within 48 hours and will be arch
12-Nov-2025 3:00 PM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Rep
29-Oct-2025 6:00 AM CST - Business Wire Ionis reports third quarter 2025 financial results and highlights progress on key programs Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results and provided key updates for the third quarter ended September 30, 2025. "The third quarter was a watershed moment for Ionis, as we made important progress advancing our Ionis-owned medicines. With two independent launches now underway, and two more anticipated in 2026, we are delivering on our goal to bring a steady cadence of new medicines to people in need, said Bre
27-Oct-2025 6:00 AM CST - Business Wire Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that detailed data from the landmark pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during a late-breaking session, titled Groundbreaking Trials in Cardiometabolic Therapeutics, at the American Heart Association (AHA) Scientific Sessions in New Orleans. Ionis previously reported positive topline results from the Phase 3 CORE and
15-Apr-2026 6:05 AM CST - Business Wire Ionis to hold first quarter 2026 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to discuss its first quarter 2026 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invente
25-Feb-2026 6:00 AM CST - Business Wire Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results and provided key updates for the fourth quarter and year ended December 31, 2025. "2025 was a defining year for Ionis, marked by the successful execution of our first two independent launches and multiple positive data readouts across our pipeline, positioning Ionis for continued success in 2026, said Brett P. Monia, Ph.D., chief executive officer of Ionis. This year,
19-Feb-2026 6:05 AM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Virtual Conference on Thursday, February 26, 2026 TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 Leerink Global Healthcare Conference on Monday, March 9, 2026 Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026 Stifel
17-Feb-2026 1:58 PM CST - Business Wire Ionis updates time for fourth quarter and full year 2025 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live webcast, previously scheduled for 11:30 a.m. Eastern Time, will now be held at 8:30 a.m. Eastern Time on Wednesday, February 25. The date of the call remains unchanged. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limi
11-Feb-2026 6:05 AM CST - Business Wire Ionis to hold fourth quarter and full year 2025 financial results webcast Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades
6-Jan-2026 6:05 AM CST - Business Wire Ionis to present at 44th Annual J.P. Morgan Healthcare Conference Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference at 8:15 a.m. PT on Tuesday, January 13, 2026. A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events. A replay will be available on the Ionis website within 48 hours and will be arch
12-Nov-2025 3:00 PM CST - Business Wire Ionis to present at upcoming investor conferences Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Rep
29-Oct-2025 6:00 AM CST - Business Wire Ionis reports third quarter 2025 financial results and highlights progress on key programs Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results and provided key updates for the third quarter ended September 30, 2025. "The third quarter was a watershed moment for Ionis, as we made important progress advancing our Ionis-owned medicines. With two independent launches now underway, and two more anticipated in 2026, we are delivering on our goal to bring a steady cadence of new medicines to people in need, said Bre
27-Oct-2025 6:00 AM CST - Business Wire Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that detailed data from the landmark pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during a late-breaking session, titled Groundbreaking Trials in Cardiometabolic Therapeutics, at the American Heart Association (AHA) Scientific Sessions in New Orleans. Ionis previously reported positive topline results from the Phase 3 CORE and
